United States. Securities and Exchange Commission
Amgen Inc. Files SEC Form 4 Disclosure
Biotech giant Amgen Inc. filed a critical disclosure on August 12, 2022, with the Securities and Exchange Commission (SEC) under Form 4. The filing reveals key information about the company's executive officers and stock ownership. As a leading biopharmaceutical company, Amgen's disclosure is closely watched by